Mar 09, 2020
D'Amore Healthcare Offers Ketamine Therapy
Jan 15, 2020
BayView Professional Associates introduces new option for treating major depressive disorder
Nov 25, 2019
Ketamine Clinics Los Angeles Featured on Emmy® Award-Winning Talk Show The Doctors
Oct 08, 2019
CT Psychiatrist Shows Titrated IV Ketamine Can STOP Suicidality
Oct 02, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Jun 06, 2019
Pacific Ketamine Institute Launches in Beverly Hills
May 21, 2019
New Data Highlights the Value of SPRAVATO(TM) (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
Apr 18, 2019
Synergistic Therapeutics Obtains US Patent for Sublingual Ketamine Treatment for Depression
Mar 27, 2019
Center for Focused Care Provides Innovative and Effective Non-Drug Treatment for Depression
Mar 05, 2019
Janssen Announces U.S. FDA Approval of SPRAVATO(TM) (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
Mar 05, 2019
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic
Jan 07, 2019
Harebrained Approach To Treating Depression With Horse Tranquilizer Turns 10 Years Old
Oct 29, 2018
New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
Sep 21, 2018
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Aug 22, 2018
COMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-resistant Depression
Jun 21, 2018
CCHR's Psychotropic Drug Awareness Campaign Extends to Suicide Warning
May 31, 2018
Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
May 05, 2018
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
Apr 25, 2018
Centers for Psychiatric Excellence (COPE) Complete Integration of Online Assessment and Tracking Software with CLINICOM(TM) to Help Improve Long-Term Patient Outcomes
Feb 26, 2018
Ketamine Now Being Used in Local Los Angeles clinic to treat Reflex Sympathetic Dystrophy (RSD) and Treatment Resistant Depression (TRD)